Moderated Poster SessionModerated Poster Session 6: BPO/LUTD 2MP-06.16: Combination of Alfuzosin XL and Tadalafil Is Superior to Monotherapy in Treating Erectile Dysfunction and Lower Urinary Tract Symptoms
Section snippets
Introduction and Objective
The potential role of PDE-5 inhibitors in treating voiding dysfunction and alpha blockers in enhancing erectile function is fertile area of research. This study was designed to ascertain the safety and efficacy of the combination of an alpha blocker, alfuzosin XL and a PDE-5 inhibitor, tadalafil on LUTS and ED versus monotherapy.
Materials and Methods
There were 151 consecutive men with previously untreated LUTS and ED who were randomized into 3 treatment groups. A group (n=50) was alfuzosin XL (10mg qd) monotherapy, B group (n=52) was tadalafil (20mg 3 times a week) monotheraphy and C group (n=49) was combination of alfuzosin XL and tadalafil for a 3 month trial. We included men with ED and BPH who scored ≤16 on the international index of erectile function-5 (IIEF-5) and an international prostate symptom score (IPSS) ≥8. The IIEF-5,
Results
At 3 months, the improvements of IIEF-5 scores in each group were +2.9, +8.1, and +10.4 (p<0.0001 vs A, p<0.005 vs B) compared to the baseline, respectively. IPSS in each group were reduced -3.5, -2.1 and -4.2 (p<0.005 vs A, p<0.001 vs B) compared to the baseline, respectively. QoL in each group were reduced -1.1, -0.8, and -1.3 (p<0.005 vs A, p<0.001 vs B) compared to the baseline, respectively. Qmax in each group were increased +3.4, +2.1, and + 4.1 (p<0.005 vs A, p<0.001 vs B) compared to
Conclusions
Treatment with a combination of an alpha blocker and a PDE–5 inhibitor was the most effective therapy to enhance both voiding and erectile function in men at risk. Larger scale, placebo controlled studies are needed to further elucidate the role of combination therapy to treat these two conditions.